Moderna Stock Jumps 9% on Phase 3 Melanoma Slot at Symposium
Moderna stock surged 9% after its Phase 3 melanoma data earned a Presidential Symposium slot, lifting Merck and BioNTech; full endpoints remain undisclosed.
Topic
Cancer Vaccines
Topic
Cancer Vaccines
Moderna and Merck Cancer Vaccine Breakthrough Reported
A Moderna and Merck breakthrough could trigger a wave of cancer vaccine development, CNN reports — an advance dermatology is watc…